Relay Therapeutics (RLAY) Operating Income (2019 - 2026)

Relay Therapeutics (RLAY) has reported Operating Income for 8 consecutive years, with -$78.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income rose 7.4% year-over-year to -$78.6 million; the TTM figure through Mar 2026 stood at -$296.5 million (up 19.22% YoY), while the FY2025 annual figure was -$302.7 million, up 18.72% from the prior year.
• Operating Income retreated to -$78.6 million in Q1 2026 per RLAY's latest filing, from -$60.6 million in the prior quarter.
• Across five years, Operating Income topped out at -$60.6 million in Q4 2025 and bottomed at -$106.0 million in Q2 2023.
• Historically, Operating Income has averaged -$83.9 million across 5 years, with a median of -$84.9 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Income jumped 59.8% — and 2023, when it plunged 61.31%.
• Relay Therapeutics' Operating Income stood at -$72.9 million in 2022, then dropped by 26.55% to -$92.2 million in 2023, then grew by 7.83% to -$85.0 million in 2024, then grew by 28.65% to -$60.6 million in 2025, then declined by 29.62% to -$78.6 million in 2026.
• Business Quant data shows RLAY's Operating Income at -$78.6 million in Q1 2026, -$60.6 million in Q4 2025, and -$80.4 million in Q3 2025.